Glomerulonephritis - Pipeline Review, H1 2018

  • ID: 4482761
  • Report
  • 201 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biogen Inc
  • Cellmid Ltd
  • Complexa Inc
  • Kyowa Hakko Kirin Co Ltd
  • Omeros Corp
  • Ra Pharmaceuticals Inc
  • MORE
Glomerulonephritis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H1 2018, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 15, 7, 12 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen Inc
  • Cellmid Ltd
  • Complexa Inc
  • Kyowa Hakko Kirin Co Ltd
  • Omeros Corp
  • Ra Pharmaceuticals Inc
  • MORE
Introduction

Glomerulonephritis - Overview

Glomerulonephritis - Therapeutics Development

Glomerulonephritis - Therapeutics Assessment

Glomerulonephritis - Companies Involved in Therapeutics Development

Glomerulonephritis - Drug Profiles

Glomerulonephritis - Dormant Projects

Glomerulonephritis - Discontinued Products

Glomerulonephritis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Glomerulonephritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Glomerulonephritis - Pipeline by Achillion Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Apellis Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Aurinia Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Biogen Inc, H1 2018

Glomerulonephritis - Pipeline by Bristol-Myers Squibb Co, H1 2018

Glomerulonephritis - Pipeline by Calliditas Therapeutics AB, H1 2018

Glomerulonephritis - Pipeline by Cellmid Ltd, H1 2018

Glomerulonephritis - Pipeline by ChemoCentryx Inc, H1 2018

Glomerulonephritis - Pipeline by Complexa Inc, H1 2018

Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2018

Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H1 2018

Glomerulonephritis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Glomerulonephritis - Pipeline by Merck KGaA, H1 2018

Glomerulonephritis - Pipeline by Omeros Corp, H1 2018

Glomerulonephritis - Pipeline by Pfizer Inc, H1 2018

Glomerulonephritis - Pipeline by Polyneuron Pharmaceuticals AG, H1 2018

Glomerulonephritis - Pipeline by Ra Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Reata Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Retrophin Inc, H1 2018

Glomerulonephritis - Pipeline by Rigel Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Sarfez Pharmaceuticals Inc, H1 2018

Glomerulonephritis - Pipeline by Shire Plc, H1 2018

Glomerulonephritis - Pipeline by Visterra Inc, H1 2018

Glomerulonephritis - Dormant Projects, H1 2018

Glomerulonephritis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Glomerulonephritis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Glomerulonephritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Achillion Pharmaceuticals Inc
  • Anthera Pharmaceuticals Inc
  • Apellis Pharmaceuticals Inc
  • Aurinia Pharmaceuticals Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Calliditas Therapeutics AB
  • Cellmid Ltd
  • ChemoCentryx Inc
  • Complexa Inc
  • Dimerix Bioscience Pty Ltd
  • GlaxoSmithKline Plc
  • Kyowa Hakko Kirin Co Ltd
  • Merck KGaA
  • Omeros Corp
  • Pfizer Inc
  • Polyneuron Pharmaceuticals AG
  • Ra Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • Retrophin Inc
  • Rigel Pharmaceuticals Inc
  • Sarfez Pharmaceuticals Inc
  • Shire Plc
  • Visterra Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll